Researchers at the CHUM Research Centre (CRCHUM) and the Peter MacCallum Cancer Centre in Australia have identified a new avenue for treating breast cancer.
In 20% to 30% of breast cancer patients, the over-expression of a particular protein (human epidermal growth factor-2) is the main cause of the proliferation of cancer cells. Over the past few years Herceptin (trastuzumab, from Roche) has become the standard treatment for this kind of cancer. While it is known that it blocks the activity of this protein, its exact mechanism of action has remained a mystery.
John Stagg, a CRCHUM researcher, Mark Smyth, with the Peter MacCallum Cancer Centre in Australia, and their colleagues have discovered that in addition to blocking cell proliferation, Herceptin also stimulates the production of interferons, which in turn activate immune cells called lymphocytes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze